Bormioli Pharma Increases Capacity in North America
The Italian company’s North American business has seen an increase of 47%.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
Bormioli Pharma, an international manufacturer of pharmaceutical packaging and medical devices based in Milan, Italy, announced on March 12, 2024 that the company’s North American sales for 2023 saw an increase of 47%. The company points to evolving infrastructure and expanded capacity in the North American market as the root of the increase.
The company expanded its focus in the United States by creating a commercial branch in the country four years ago. An FDA-approved warehouse and dedicated product offerings have been established that are compatible with regional standards. This enabled the company’s US customers to streamline purchasing processes and reduce supply chain complexity, according to Bormioli.
In a press release, Bormioli points to the significant growth in the pharmaceutical glass vials market as a part of its success, with the US market as a major contributor. The company signed a contract with a US-based allergen immunotherapy company for the supply of vertically integrated packaging kits that include aluminum seals, rubber stoppers, Type I molded glass vials, and Type I tubular glass expansion 33 vials.
The company has also committed to sustainable pharma packaging and increased use of sustainable raw materials in 2023 to 45%. It aims to achieve 50% of sustainable raw materials in its pharmaceutical packaging products by 2025. The company conducted analyses of its sustainable packaging and partnered with a clean technology company to use 100% recycled resin for developing a novel pharmaceutical packaging bottle.
“As we grow our presence in North America and expand our capabilities to meet regional standards, we are committed to the partnerships that enable us to broaden our reach,” said Johann Depperschmidt, Bormioli Pharma’s head of Sales, Americas, in a press release. “To best serve our North American customers, we've adapted our manufacturing processes to produce Type I Glass expansion 33 vials in our European facilities, ensuring robust production and backup. We have an on-site, dedicated US sales team and a local warehouse, and we look forward to expanding these resources further in 2024. Additionally, we are collaborating with a US-based sterilization company to prepare ready-to-use packaging kits—a partnership we believe is a significant step forward in ensuring that quality healthcare becomes a more accessible reality for people everywhere.”
“Our momentous growth in the North American market embodies our dedication to meeting and exceeding the evolving needs of this dynamic market,” the company’s CEO, Andrea Lodetti, said in the release. “We are not just expanding our footprint but also enhancing our efficiency and adaptability. This growth aligns perfectly with our mission to provide innovative and sustainable pharmaceutical packaging solutions, and we are proud to say that our growth is not only robust but also responsible.”
Bormioli Pharma offers glass and plastic bottles, plastic and aluminum closures, and accessories in more than 100 countries and nine plants in Europe. The company will be showcasing its products and services at DCAT Week 2024 in New York City, March 18–21, 2024.
Source: Bormioli Pharma
